The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Breast Neoplasms
COMBINATION_PRODUCT: Fecal microbial diversity
Pathologic Complete Response (pCR), Defined as ypT0/Tis ypN0, ypT0 ypN0, and ypT0/Tis, Week 24
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.